SCHEMBL956095

SCHEMBL956095

CCOC(=O)CC(=O)CCc1ccccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.54
CYP4A11 Q02928 2/20 0.54
MAPT P10636 1/20 0.47
ALDH1A1 P00352 3/20 0.46
NLRP3 Q96P20 2/20 0.46
HPGD P15428 1/20 0.45
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
PLAAT3 P53816 1/20 0.44
PLAAT5 Q96KN8 1/20 0.44
PLAAT2 Q9NWW9 1/20 0.44
PLAAT4 Q9UL19 1/20 0.44
HTT P42858 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
TAAR1 Q96RJ0 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9394814 0.88 CYP4F2 (0.69) CYP4F2CYP4A11MAPTALDH1A1NLRP3
SCHEMBL12602245 0.85 CYP4F2 (0.56) CYP4F2CYP4A11ALDH1A1NLRP3HTT
SCHEMBL10955526 0.85 ALDH1A1 (0.48) CYP4F2CYP4A11MAPTALDH1A1NLRP3
SCHEMBL3951620 0.83 PLAAT3 (0.51) MAPTALDH1A1PLAAT3PLAAT5PLAAT2
SCHEMBL957050 0.82 CYP4F2 (0.54) CYP4F2CYP4A11MAPTALDH1A1NLRP3
SCHEMBL956957 0.82 CYP4F2 (0.54) CYP4F2CYP4A11MAPTALDH1A1NLRP3
SCHEMBL28873178 0.81 CYP4F2 (0.52) CYP4F2CYP4A11ALDH1A1POLB
SCHEMBL7323440 0.79 PLAAT3 (0.49) CYP4F2CYP4A11MAPTALDH1A1HPGD
SCHEMBL7331092 0.79 TAAR1 (0.54) PLAAT3PLAAT5PLAAT2PLAAT4TAAR1
SCHEMBL717900 0.78 TDP1 (0.56) CYP4F2CYP4A11MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009429-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 NOVARTIS AG (CH) 2011-01-13 US disclosed
US-4042596-A 2-Alkyl-5-phenethyl-4-oxazolecarboxylic acids and derivatives SANDOZ, INC. (US) 1977-08-16 US disclosed
US-3994915-A Preparation of substituted oxazoles SANDOZ, INC. (US) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009429-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 CXCR2, CXCR1, CXCR3 CYP4F2 1678/4885CYP4A11 1251/4885MAPT 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.